GlassScriptPhysician profile
Gary R Nelson
NPI 1245209634
$3,064.52
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,293 · 2020: $379 · 2021: $265 · 2022: $127.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $715.67 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $367.80 | 2019 | |
| Glaxosmithkline, LLC. | $181.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.77 | 2019 | |
| Pfizer INC. | $150.64 | 2019 | |
| Lilly USA, LLC | $145.90 | 2019 | |
| Abbvie INC. | $145.69 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $144.50 | 2019-2021 | |
| Amgen INC. | $128.65 | 2019 | |
| Amarin Pharma, INC. | $124.60 | 2019 | |
| Novo Nordisk INC | $121.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $110.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.19 | 2019 | |
| Abbott Laboratories | $72.27 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $62.21 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $59.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $56.84 | 2019 | |
| Allergan, INC. | $45.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.55 | 2019 | |
| Collegium Pharmaceutical, INC. | $25.47 | 2019 | |
| Mylan Specialty L.P. | $16.77 | 2019 | |
| Genentech USA, INC. | $16.69 | 2019 | |
| Merck Sharp & Dohme LLC | $14.36 | 2019 | |
| Circassia INC. | $13.63 | 2019 | |
| Horizon Therapeutics Plc | $11.42 | 2019 | |
| Biodelivery Sciences International, INC. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.